About this trial
The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combination with one or two breast radiologists to the number of breast cancers detected after standard independent double reading in BreastScreen Norway. The aims of the study is to prove that screening interpretation with AI in combination with one or two radiologists (the intervention) is non-inferior to standard interpretation procedure.
Eligibility criteria
Qualifiers
Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent
Disqualifiers
Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent
Trial design
Treatments tested in this trial
- AI assisted mammography screening interpretation
- Standard mammography screening interpretation
Treatment groups
Sponsors and collaborators
Norwegian Institute of Public Health
Lead sponsor
Helse Vest
Collaborator
Helse Midt-Norge
Collaborator
Helse Nord
Collaborator
Norwegian Cancer Society
Collaborator